Here’s the complete debunk of your FUD
1) What the 2015-341 family actually is
• Nature of claims: 2015-341 covers using an autologous tumor-lysate–pulsed dendritic-cell vaccine together with PD-1/PD-L1 checkpoint blockade in gliomas. That is a method-of-treatment patent family.
• Scientific substrate: The “ATL-DC” described is the same dendritic-cell vaccine platform pioneered at UCLA that NWBO commercializes as DCVax-L. The filing extends use claims to combinations; it does not introduce a new cell product.
2) Rights chain and control
• Origin and license: DCVax-L originates at UCLA. NWBO holds the exclusive commercial license for therapeutic use in brain cancers.
• Continuations and co-applicants: Follow-on filings list NWBO scientists and affiliates among the applicants. That reflects either co-ownership or exclusive commercial rights to the combination claims.
• Layered IP model: NWBO’s composition/manufacture claims protect how the DC is made and matured. UCLA’s 2015-341 claims protect how the very same vaccine is used in combination regimens. The portfolios interlock.
3) “ATL-DC” vs “DCVax-L”
• Terminology: “ATL-DC” is the academic label UCLA uses in papers and IITs. “DCVax-L” is the regulated, GMP-standardized product manufactured for commercial supply.
• Process lineage: Both rely on autologous dendritic cells pulsed with patient tumor lysate. NWBO’s process work industrializes this under GMP and scale-out control.
• Academic production: UCLA can produce small, non-commercial batches under trial exemptions. That activity sits under UCLA’s rights and coexists with NWBO’s commercial rights; it does not create a rival product line.
4) The usual FUD pivots, addressed
• “Separate Liau patent = separate vaccine.”
– The claim conflates method claims with composition claims. A new method claim that pairs DCVax-style cells with PD-1 blockade builds on the vaccine; it doesn’t split it.
• “UCLA kept the good stuff.”
– The continuation chain and applicant list show integration into NWBO’s IP sphere. Academic inventors and commercial developers sharing a chain is the normal path from bench to market.
• “ATL-DC differs in maturation phenotype, so it’s different.”
– Manufacturing recipes can evolve across time and sponsors. What matters is the core construct (patient-specific DCs pulsed with autologous tumor lysate) and exclusive field-of-use. On both, ATL-DC and DCVax-L align.
• “Combination patents don’t strengthen NWBO.”
– Combination method rights are commercially valuable. They shape freedom-to-operate in the checkpoint era and raise the bar for copycats attempting DC-plus-PD-1 regimens.
5) Why this strengthens the thesis
• Defensive moat expands: NWBO covers the product (how to make and release it) and, via the UCLA chain, the regimens most likely to matter in practice (DCVax-L with PD-1).
• Clinical roadmap coherence: UCLA’s IITs (e.g., pembrolizumab + ATL-DC) and NWBO’s platform IP are aligned, not competing. Success in IITs feeds the commercial label-expansion story.
• Regulator-facing clarity: One lineage from UCLA lab vaccine to DCVax-L commercial supply reads cleaner to regulators and payers than dueling product narratives.
6) What would actually undermine NWBO (and what we do not see)
• Evidence of a distinct composition owned outside NWBO’s license.
• A UCLA assignment or license that excludes NWBO from clinical brain-cancer use.
• IIT language asserting a different vaccine construct rather than the same tumor-lysate DC approach under an academic label.
Investor takeaway
The 2015-341 case and its continuations extend the DCVax platform into checkpoint combinations. They do not establish a parallel vaccine outside NWBO’s control. “ATL-DC” and “DCVax-L” represent one scientific lineage operating in two settings: academic IITs and commercial GMP. For investors, that means a broader moat and a clearer path to combination strategies, which is where value accrues in modern immuno-oncology.
Market Data 
Markets 
AI
